Renovaro Enters into Agreement with BioSymetrics to Advance AI-Driven Biomarker Discovery and Precision Medicine
Thursday, February 27, 2025
Renovaro Biosciences has signed a definitive agreement to merge with BioSymetrics.
The merger aims to strengthen Renovaro’s data repository, improve biomarker discovery, accelerate translational research, and advance precision medicine solutions for cancer and other serious diseases.
BioSymetrics’ proprietary AI platform, Elion, plays a key role in this collaboration. The platform uses AI and machine learning to uncover complex biological relationships, facilitating the identification of diagnostics and therapeutics.
Additionally, BioSymetrics’ Phenograph technology enables the mapping of human clinical signals to prioritised therapeutic targets, improving the speed and accuracy of target and biomarker identification. The company’s AI-driven in vivo modelling and machine vision systems allow high-throughput phenotypic screening, identifying subtle biological responses with high precision.
This data-driven approach enhances the validation of therapeutics by integrating computational insights with biological evidence. BioSymetrics has established platform and analytical partnerships with leading pharmaceutical companies, including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
By incorporating the Elion platform into its operations, the combined company aims to streamline biomarker research, improve the identification of therapeutic targets, and enhance research efficiency. This integration is expected to shorten discovery timelines and support the development of more effective treatments.
BioSymetrics’ AI technology has been instrumental in identifying novel disease signatures and optimising precision medicine strategies. Following the merger, Renovaro will gain access to advanced computational tools that support patient stratification, predict treatment responses, and improve therapeutic decision-making.
The merger highlights a shared commitment to using AI and data-driven approaches to improve healthcare outcomes.
The focus will be on combining AI-powered biomarker discovery with innovative drug development to deliver more precise and effective treatments globally.
Source: renovarogroup.com
